• Հայերեն
  • Русский
  • English
pharm.am
  • Home
  • About us
  • Main Functions
  • Committees and Councils
  • News and Announcements
  • Publications
  • Veterinary medicines
  • Contacts

Dear Healthcare Professional Letter

Metamizole: Risk of drug-induced liver injury
Myfortic (mycophenolic acid): risk of teratogenicity
Actemra
Tivicay (dolutegravir): updated information on neural tube defects reported in Tsepamo Study, Botswana
Tecentriq (atezolizumab), identified risk of severe cutaneous adverse reactions (SCARs) direct healthcare professional communication (DHPC)
Cellcept (mycophenolate mopetil)
Retinoids (Isotretinoin) - update on teratogenicity and neuropsychiatric disorders Direct Healthcare
Important information about Mabthera
Important information on Dacarbazine medac 200 mg: decreased stability after reconstitution
Leuprorelin-containing depot products: need to strictly follow instructions for reconstitution and administration to reduce the risk of handling errors that may result in lack of efficacy

Page 2 of 6

  • 1
  • 2
  • 3
  • 4
  • ...
  • 6
  • Register
  • Guide to using "Database of registered medicines"
  • Drugs safety profile
  • ONLINE report about adverse effect of medicine

PUBLICATIONS

  • "Drugs and Medicines" Information Bulletin
  • “Safety of drugs” information leaflet
  • Dear Healthcare Professional Letter
  • Booklets

  • RSS
  • Facebook
  • Twitter
  • Home
  • About us
  • Main Functions
  • Committees and Councils
  • News and Announcements
  • Publications
  • Veterinary drugs
  • Contacts
  • SiteMap

Back to Top

© 2022 pharm.am